Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2007; 13(6): 930-933
Published online Feb 14, 2007. doi: 10.3748/wjg.v13.i6.930
Published online Feb 14, 2007. doi: 10.3748/wjg.v13.i6.930
Table 1 Demographic data and outcomes of two enrolled groups
| Data | Group A (n = 80) | Group B (n = 80) |
| Mean age (yr) (mean ± SD) | 52.4 ± 13 | 53.1 ± 12.3 |
| Gender (male/female) | 55/25 | 57/23 |
| Eradication rate | ||
| Intension-to-treat | 85% (68/80) | 83.75% (67/80) |
| Per-protocol | 88% (68/77) | 89% (67/75) |
| Adverse events | ||
| Mild | 20% (15) | 22% (17) |
| Moderate | 5% (5) | 8% (6) |
| Severe | 1.25% (1) | 2.5% (2) |
| Compliance | 98% (78/80) | 96% (77/80) |
-
Citation: Keshavarz AA, Bashiri H, Rahbar M. Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for
H pylori eradication in Iranian population. World J Gastroenterol 2007; 13(6): 930-933 - URL: https://www.wjgnet.com/1007-9327/full/v13/i6/930.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i6.930
